Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Singer

Showing results (451-460 of 649) with videos related to

Pageof 65
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2019
Prediction of Distant Recurrence Using EndoPredict Among Women with ER<sup>+</sup>, HER2<sup>-</sup> Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy OnlyMartin Filipits, Peter Dubsky, Margaretha Rudas, et al.
Wiener Klinische Wochenschrift|April 3, 2023
Axillary lymph node status and invasive lobular breast cancer : Analysis of the Clinical Tumor Register of the AGO AustriaSabine Danzinger, Karin Pöckl, Gerit Kronawetter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trialErnst Kubista, Juan V M Planellas Gomez, Mitch Dowsett, et al.
Journal of Cancer Research and Clinical Oncology|May 3, 2005
The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 statusWolfgang J Köstler, Thomas Brodowicz, Gernot Hudelist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2011
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancerZsuzsanna Bago-Horvath, Margaretha Rudas, Peter Dubsky, et al.
ESMO Open|December 31, 2025
A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutationsJ Ródon, H-T Arkenau, P Funchain, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trialChristian F Singer, Franz Koenig, Stephanie Kacerovsky-Strobl, et al.
International Journal of Cancer|January 14, 2018
The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriersKwang-Pil Ko, Shana J Kim, Tomasz Huzarski, et al.
Breast Cancer Research and Treatment|January 31, 2012
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II studyIrene Kuter, Julia M W Gee, Roberto Hegg, et al.
Breast Cancer Research and Treatment|October 16, 2015
Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?John Semple, Kelly A Metcalfe, Jan Lubinski, et al.
Pageof 65

Showing results (451-460 of 649) with videos related to

Sort By:
Pageof 65
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2019
Prediction of Distant Recurrence Using EndoPredict Among Women with ER<sup>+</sup>, HER2<sup>-</sup> Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy OnlyMartin Filipits, Peter Dubsky, Margaretha Rudas, et al.
Wiener Klinische Wochenschrift|April 3, 2023
Axillary lymph node status and invasive lobular breast cancer : Analysis of the Clinical Tumor Register of the AGO AustriaSabine Danzinger, Karin Pöckl, Gerit Kronawetter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trialErnst Kubista, Juan V M Planellas Gomez, Mitch Dowsett, et al.
Journal of Cancer Research and Clinical Oncology|May 3, 2005
The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 statusWolfgang J Köstler, Thomas Brodowicz, Gernot Hudelist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2011
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancerZsuzsanna Bago-Horvath, Margaretha Rudas, Peter Dubsky, et al.
ESMO Open|December 31, 2025
A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutationsJ Ródon, H-T Arkenau, P Funchain, et al.
Breast (Edinburgh, Scotland)|January 7, 2026
HER2/CEP17 ratio is associated with pCR after HER2-directed neoadjuvant treatment in the phase III NeoALTTO trialChristian F Singer, Franz Koenig, Stephanie Kacerovsky-Strobl, et al.
International Journal of Cancer|January 14, 2018
The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriersKwang-Pil Ko, Shana J Kim, Tomasz Huzarski, et al.
Breast Cancer Research and Treatment|January 31, 2012
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II studyIrene Kuter, Julia M W Gee, Roberto Hegg, et al.
Breast Cancer Research and Treatment|October 16, 2015
Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers?John Semple, Kelly A Metcalfe, Jan Lubinski, et al.
Pageof 65